31P/1H MRI Measurement of Bone Mineralization
31P/1H MRI 骨矿化测量
基本信息
- 批准号:6924826
- 负责人:
- 金额:$ 37.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-05-03 至 2009-02-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant):
An NIH consensus development panel concluded in 2001 that in the United States alone, 10 million people already have osteoporosis, and 18 million more have low bone mass. Patients with low bone mass due to osteomalacia usually remain for many years misdiagnosed as only having osteoporosis, since radiographs plus blood and urine measurements frequently fail to distinguish the two conditions. Patients with osteomalacia have impaired bone mineralization, and may in addition have a reduced amount of bone tissue, whereas patients with osteoporosis have a reduced amount of bone which is normally-mineralized. At present an invasive bone biopsy is the only way to discriminate osteomalacia from osteoporosis with confidence. Confounding osteomalacia with osteoporosis in individual patients leads to inappropriate therapy.
The purpose of the proposed 31P/1H solid state magnetic resonance imaging (SMRI) measurement of bone mineralization is to provide critically needed information about the relative proportions of bone mineral and bone matrix in a given volume of bone substance that is unattainable by any other noninvasive methods including CT and high resolution liquid state MRI. The SMRI method targets a so-called soft solid regime. The 31P NMR signals of bone mineral and some portion of the 'H NMR signals of solid bone matrix fall in this regime. Quantitative 31P SMRI yields a good representation of the mineral density in bone, and quantitative water and fat suppressed [H projection MRI (WASPI) provides the measurement of the matrix density of bone. Combining these two measurements yields the degree of bone mineralization.
In the proposed project, this novel MRI technology will be further developed and implemented in a whole body MRI scanner. It will be evaluated first in live swine with osteomalacia and controls, then in human subjects with osteoarthritis, all against gold standard chemical and gravimetric analyses of the associated bone specimens harvested from the animals or resected during total knee replacement. Finally, the proposed SMRI will be evaluated in patients who have been clinically diagnosed with osteoporosis and/or osteomalacia.
If this technology is successful, it would identify osteomalacia non-invasively in patients with low bone density and benefit their medical care, because treatment of osteomalacia is dramatically effective, and increases bone mineral density and bone strength much more than any available treatment for osteoporosis.
描述(由申请人提供):
NIH 共识制定小组于 2001 年得出结论,仅在美国,就有 1000 万人患有骨质疏松症,还有 1800 万人骨量低。由于骨软化症而导致骨量低的患者通常会被误诊为仅患有骨质疏松症多年,因为射线照片加上血液和尿液测量常常无法区分这两种情况。骨软化症患者的骨矿化受损,并且骨组织量可能减少,而骨质疏松症患者的正常矿化骨量减少。目前,侵入性骨活检是可靠地区分骨软化症和骨质疏松症的唯一方法。将个别患者的骨软化症与骨质疏松症混为一谈会导致治疗不当。
所提出的 31P/1H 固态磁共振成像 (SMRI) 骨矿化测量的目的是提供关于给定体积骨物质中骨矿物质和骨基质相对比例的急需信息,这是任何其他非侵入性方法(包括 CT 和高分辨率液态 MRI)无法获得的信息。 SMRI 方法的目标是所谓的软固态状态。骨矿物质的 31P NMR 信号和固体骨基质的 1H NMR 信号的某些部分属于该范围。定量 31P SMRI 可以很好地表示骨骼中的矿物质密度,定量水和脂肪抑制 [H 投影 MRI (WASPI) 可以测量骨骼的基质密度。结合这两种测量结果即可得出骨矿化程度。
在拟议的项目中,这种新颖的 MRI 技术将在全身 MRI 扫描仪中得到进一步开发和实施。首先将在患有骨软化症的活猪和对照组中进行评估,然后在患有骨关节炎的人类受试者中进行评估,所有这些都针对从动物身上采集或在全膝关节置换期间切除的相关骨样本进行金标准化学和重量分析。最后,所提出的 SMRI 将在临床诊断为骨质疏松症和/或骨软化症的患者中进行评估。
如果这项技术成功,它将能够非侵入性地识别低骨密度患者的骨软化症,并有利于他们的医疗护理,因为骨软化症的治疗非常有效,并且比任何现有的骨质疏松症治疗方法都更能增加骨矿物质密度和骨强度。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YAOTANG WU其他文献
YAOTANG WU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YAOTANG WU', 18)}}的其他基金
31P/1H MRI Measurement of Bone Mineralization
31P/1H MRI 骨矿化测量
- 批准号:
7061742 - 财政年份:2005
- 资助金额:
$ 37.3万 - 项目类别:
31P/1H MRI Measurement of Bone Mineralization
31P/1H MRI 骨矿化测量
- 批准号:
7176794 - 财政年份:2005
- 资助金额:
$ 37.3万 - 项目类别:
31P/1H MRI Measurement of Bone Mineralization
31P/1H MRI 骨矿化测量
- 批准号:
7384510 - 财政年份:2005
- 资助金额:
$ 37.3万 - 项目类别:
相似海外基金
Pathophysiology of bone disorder in light of epigenetic alteration and comprehensive network of transcription factors
表观遗传改变和转录因子综合网络的骨病病理生理学
- 批准号:
20H03458 - 财政年份:2020
- 资助金额:
$ 37.3万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Acute kidney injury-induced mineral and bone disorder: concept and characterization
急性肾损伤引起的矿物质和骨疾病:概念和特征
- 批准号:
20K08618 - 财政年份:2020
- 资助金额:
$ 37.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Vitamin D Genetics and Racial Differences in Pediatric Chronic Kidney Disease-Mineral and Bone Disorder
儿科慢性肾脏病 - 矿物质和骨骼疾病的维生素 D 遗传学和种族差异
- 批准号:
10380577 - 财政年份:2020
- 资助金额:
$ 37.3万 - 项目类别:
Vitamin D Genetics and Racial Differences in Pediatric Chronic Kidney Disease-Mineral and Bone Disorder
儿科慢性肾脏病 - 矿物质和骨骼疾病的维生素 D 遗传学和种族差异
- 批准号:
10592364 - 财政年份:2020
- 资助金额:
$ 37.3万 - 项目类别:
Salt inducible kinases: novel therapeutic targets for chronic kidney disease mineral and bone disorder (CKD-MBD)
盐诱导激酶:慢性肾病矿物质和骨疾病 (CKD-MBD) 的新治疗靶点
- 批准号:
413021 - 财政年份:2019
- 资助金额:
$ 37.3万 - 项目类别:
Fellowship Programs
Fluoride and Human Health: Assessing Novel Biomarkers in Detecting Bone Disorder
氟化物与人类健康:评估检测骨疾病的新型生物标志物
- 批准号:
9891065 - 财政年份:2018
- 资助金额:
$ 37.3万 - 项目类别:
Systems biology approach to the management of chronic kidney disease-mineral bone disorder
治疗慢性肾病-矿物质性骨病的系统生物学方法
- 批准号:
10310403 - 财政年份:2018
- 资助金额:
$ 37.3万 - 项目类别:
Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) Syndrome in the Diabetic, Neuropathic Foot
糖尿病神经性足部的慢性肾病-矿物质骨紊乱 (CKD-MBD) 综合征
- 批准号:
10734640 - 财政年份:2016
- 资助金额:
$ 37.3万 - 项目类别:
Fluoride and human health: Assessing novel biomarkers in detecting bone disorder
氟化物与人类健康:评估检测骨疾病的新型生物标志物
- 批准号:
9057043 - 财政年份:2015
- 资助金额:
$ 37.3万 - 项目类别:
Beneficial effects of rice endosperm and bran protein on chronic kidney disease-mineral bone disorder
稻米胚乳和麸皮蛋白对慢性肾病-矿物质性骨病的有益作用
- 批准号:
15K21004 - 财政年份:2015
- 资助金额:
$ 37.3万 - 项目类别:
Grant-in-Aid for Young Scientists (B)














{{item.name}}会员




